Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...
No appointments or technicians are needed for this setup.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results